Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment

Background and aimsManagement of Type 1 Diabetes (T1D) in young children is challenging. A poor glycaemic control during the first years of disease increases the risk of microvascular complications. Moreover, hyperglycaemia and glucose variability have a negative effect on the brain development. Adv...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniele Franzone, Giordano Spacco, Andrea Piano, Giulia Siri, Giacomo Tantari, Giuseppe d’Annunzio, Maria Grazia Calevo, Mohamad Maghnie, Nicola Minuto, Marta Bassi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1590964/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849430701724663808
author Daniele Franzone
Giordano Spacco
Andrea Piano
Giulia Siri
Giacomo Tantari
Giuseppe d’Annunzio
Maria Grazia Calevo
Mohamad Maghnie
Mohamad Maghnie
Nicola Minuto
Marta Bassi
Marta Bassi
author_facet Daniele Franzone
Giordano Spacco
Andrea Piano
Giulia Siri
Giacomo Tantari
Giuseppe d’Annunzio
Maria Grazia Calevo
Mohamad Maghnie
Mohamad Maghnie
Nicola Minuto
Marta Bassi
Marta Bassi
author_sort Daniele Franzone
collection DOAJ
description Background and aimsManagement of Type 1 Diabetes (T1D) in young children is challenging. A poor glycaemic control during the first years of disease increases the risk of microvascular complications. Moreover, hyperglycaemia and glucose variability have a negative effect on the brain development. Advanced hybrid closed loop (AHCL) systems demonstrated to improve glycaemic control in adolescents and adults with T1D although data on younger children are limited. The aim of the study was to evaluate the safety and the effectiveness of AHCL systems’ off-label use in children aged less than 7 years.MethodsA retrospective single-center study on T1D patients aged less than 7 years using AHCL systems was conducted. Glycated hemoglobin (HbA1c) values, Continuous Glucose Monitoring (CGM) and insulin requirement data were collected at T0 (AHCL starting), T1 (1-month), T2 (3-months) and T3 (1-year).Results41 patients were included in the study. No episode of severe hypoglycaemia occurred. Three patients experienced an episode of ketoacidosis (DKA) due to insulin delivery set occlusion. During the 12-months study period, an improvement in HbA1c value (7.50 vs 6.59%, p<0.001), Time in Range (TIR, +10.21%, p<0.001) and Time in Tight Range (TITR, +7.56%, p=0.003) were observed, with a reduction in time in hyperglycaemia and without an increase in time in hypoglycaemia. The AHCL use increased insulin requirement at 12-months, especially in bolus doses (p<0.001).ConclusionsAlthough AHCL systems are not currently approved for this age group, we have demonstrated their safety and efficacy in children under 7 years with T1D. The use of these systems resulted in significant improvement in glycaemic control without increasing the risk of hypoglycaemia. The impact of early glycaemic control on brain development during the first years of life may support the early introduction of AHCL systems in very young children with T1D. It is essential to gather data that could support the approval of these systems for use in younger age groups.
format Article
id doaj-art-ec844d91d875425887d68a475e8ec7a5
institution Kabale University
issn 1664-2392
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-ec844d91d875425887d68a475e8ec7a52025-08-20T03:27:52ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-06-011610.3389/fendo.2025.15909641590964Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessmentDaniele Franzone0Giordano Spacco1Andrea Piano2Giulia Siri3Giacomo Tantari4Giuseppe d’Annunzio5Maria Grazia Calevo6Mohamad Maghnie7Mohamad Maghnie8Nicola Minuto9Marta Bassi10Marta Bassi11DINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, ItalyDINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, ItalyDINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, ItalyDepartment of Pediatrics and Neonatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Savona, ItalyPediatric Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, ItalyPediatric Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, ItalyBiostatistics Unit, Scientific Directorate, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, ItalyDINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, ItalyPediatric Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, ItalyDepartment of Pediatrics and Neonatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Savona, ItalyDINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, ItalyPediatric Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, ItalyBackground and aimsManagement of Type 1 Diabetes (T1D) in young children is challenging. A poor glycaemic control during the first years of disease increases the risk of microvascular complications. Moreover, hyperglycaemia and glucose variability have a negative effect on the brain development. Advanced hybrid closed loop (AHCL) systems demonstrated to improve glycaemic control in adolescents and adults with T1D although data on younger children are limited. The aim of the study was to evaluate the safety and the effectiveness of AHCL systems’ off-label use in children aged less than 7 years.MethodsA retrospective single-center study on T1D patients aged less than 7 years using AHCL systems was conducted. Glycated hemoglobin (HbA1c) values, Continuous Glucose Monitoring (CGM) and insulin requirement data were collected at T0 (AHCL starting), T1 (1-month), T2 (3-months) and T3 (1-year).Results41 patients were included in the study. No episode of severe hypoglycaemia occurred. Three patients experienced an episode of ketoacidosis (DKA) due to insulin delivery set occlusion. During the 12-months study period, an improvement in HbA1c value (7.50 vs 6.59%, p<0.001), Time in Range (TIR, +10.21%, p<0.001) and Time in Tight Range (TITR, +7.56%, p=0.003) were observed, with a reduction in time in hyperglycaemia and without an increase in time in hypoglycaemia. The AHCL use increased insulin requirement at 12-months, especially in bolus doses (p<0.001).ConclusionsAlthough AHCL systems are not currently approved for this age group, we have demonstrated their safety and efficacy in children under 7 years with T1D. The use of these systems resulted in significant improvement in glycaemic control without increasing the risk of hypoglycaemia. The impact of early glycaemic control on brain development during the first years of life may support the early introduction of AHCL systems in very young children with T1D. It is essential to gather data that could support the approval of these systems for use in younger age groups.https://www.frontiersin.org/articles/10.3389/fendo.2025.1590964/fulltype 1 diabetestoddlersAID (automated insulin delivery)AHCL (advanced hybrid closed loop)off-label
spellingShingle Daniele Franzone
Giordano Spacco
Andrea Piano
Giulia Siri
Giacomo Tantari
Giuseppe d’Annunzio
Maria Grazia Calevo
Mohamad Maghnie
Mohamad Maghnie
Nicola Minuto
Marta Bassi
Marta Bassi
Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
Frontiers in Endocrinology
type 1 diabetes
toddlers
AID (automated insulin delivery)
AHCL (advanced hybrid closed loop)
off-label
title Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
title_full Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
title_fullStr Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
title_full_unstemmed Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
title_short Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment
title_sort real world evaluation of safety and efficacy of ahcl systems in young children with type 1 diabetes a 1 year assessment
topic type 1 diabetes
toddlers
AID (automated insulin delivery)
AHCL (advanced hybrid closed loop)
off-label
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1590964/full
work_keys_str_mv AT danielefranzone realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT giordanospacco realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT andreapiano realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT giuliasiri realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT giacomotantari realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT giuseppedannunzio realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT mariagraziacalevo realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT mohamadmaghnie realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT mohamadmaghnie realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT nicolaminuto realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT martabassi realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment
AT martabassi realworldevaluationofsafetyandefficacyofahclsystemsinyoungchildrenwithtype1diabetesa1yearassessment